Regal Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Regal Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-3,524	Closed	-$231K	–	280
2015 Q4	$231K	Buy	3,524 +102	+3%	+$6.3K	0.06%	229
2015 Q3	$193K	Buy	+3,422	New	+$222K	0.05%	236
2013 Q3	–	Sell	-51	Closed	-$2K	–	936
2013 Q2	$2K	Buy	+51	New	+$1.99K	﹤0.01%	809

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regal Investment Advisors's TEVA Position: Q1 2016 in Review

Regal Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 3,524 shares — an estimated $231K sold.

Regal Investment Advisors first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $231K in Q4 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Regal Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Regal Investment Advisors sold 3,524 Teva Pharmaceuticals shares in Q1 2016, an estimated $231K.
Regal Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
Regal Investment Advisors's Teva Pharmaceuticals position peaked at $231K in Q4 2015.
836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Regal Investment Advisors's 13F filing for Q1 2016, filed 16 May 2016.